期刊文献+

3项肾小球滤过率内源性标志物的临床应用评价 被引量:5

Clinical evaluation of three different endogenous markers for calculating glomerular filtration rate
下载PDF
导出
摘要 目的探讨3项肾小球滤过率内源性标志物的临床应用价值。方法测定57例肾脏疾病患者和50例健康人的血清CystatinC、β2微球蛋白(β2-M)、血清肌酐(Scr)及尿肌酐浓度,计算Ccr值后进行统计分析。结果当肾脏有轻微损伤时,Cys-tatinC出现明显变化,血清β2-M、Scr与健康对照组相比差异无统计学意义;3项肾小球滤过率内源性标志物与Ccr之间均呈高度负相关,血清CystatinC与Ccr相关性的密切程度高于其他两者。结论血清CystatinC的敏感性、特异性优于Scr和血清β2-M,是GFR最理想的内源性标志物,应纳入肾功能常规检查。 Objective To study the clinical significance of three different endogenous markers for calculating glomerular filtration rate(GFR).Methods 57 cases of patients with kidney diseases and 50 cases of healthy controls were enrolled and determined for serum Cystatin C,β2 microglobulin (β2-M),creatinine (Scr) and urinary creatinine concentration,then creatinine clearance rate was calculated and statistically analyzed.Results In patients with slight kidney injury,serum Cystatin C level significantly changed,but serum levels of β2-M and Scr showed no difference,when being compared with control group.There were significantly negative correlations between the three endogenous markers for calculating GFR and Ccr level,and serum level of Cystatin C was more correlated with Ccr level than the other two markers.Conclusion The sensitivity and specificity of serum Cystatin C might be superior to Scr and β2-M,could be the most ideal endogenous markers for calculating GFR and should be included in routine examination for renal function.
作者 李黎
出处 《国际检验医学杂志》 CAS 2012年第2期170-171,共2页 International Journal of Laboratory Medicine
关键词 肾小球滤过率 内源性标志物 临床应用 glomerular filtration rate endogenous marker clinical application
  • 相关文献

参考文献13

二级参考文献69

共引文献164

同被引文献37

  • 1蔡钢强,垢敬,焦连亭.胱抑素C的生物学特性及临床应用评价[J].国际检验医学杂志,2006,27(5):457-460. 被引量:57
  • 2叶任高,陆再英.内科学[M].6版.北京:人民卫生出版社,2005.948-987.
  • 3贾民宜.诊断学[M].3版.北京:人民卫生出版社,1997:222.
  • 4Hoek FJ, Kemperman, FA, Kredier RT. A comparison between Cystatin C, plasma creatinine and the Cockroft and Grult formula for the estimation of glomerular filtrateion rate[J]. Nephrol Dial Transplant, 2003, 18 (10): 2024- 2031.
  • 5National Committee for Clinical Standards. Method comparison and bias estimation using patient samples; approved guideline-second edition [ S ]. EP9-A2, NCCI_S,2002.
  • 6Hossain MA, Emara M, E1 Moselhi H, et al. Comparing measures of cystatin C in human sera by three methods [ J]. Am J Nephrol, 2009 , 29 (5) : 381-391.
  • 7National Committee for Clinical Standards. Method comparison and bias estimation using patient samples; approved guideline [ S ]. EP9-A, NCCLS, 1995.
  • 8International Organization for Standardization. In vitro diagnostic medical devices. Measurement of quanti- ties in biological samples. Metrological traceability of values assigned to calibrators and control materials [S]. IS017511,IS0, 2003.
  • 9Grubb A, Blirup-Jensen S, Lindstrom V. First certified reference material for cystatin C in human serum ERM-DA471/IFCC [ J ]. Clin Chem Lab Med, 2010, 48 (11) : 1619-1621.
  • 10Voskoboev NV, Larson TS, Rule AD, et al. Importance of cystatin C assay standardization [ J ]. Clin Chem, 2011, 57 (8): 1209-1211.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部